{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:31:57Z","timestamp":1793680317845,"version":"4.5.1"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi250248-4\"><jats:title>Importance<\/jats:title><jats:p>Treatment retention for pregnant individuals with opioid use disorder (OUD) is critical, especially during the high-potency synthetic opioid (HPSO) era. Current data on the relationship between medication for opioid use disorder (MOUD) receipt in specialty substance use treatment facilities and retention are needed for this population.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250248-5\"><jats:title>Objective<\/jats:title><jats:p>To examine the association between MOUD inclusion in treatment and 6-month treatment retention among pregnant individuals with OUD in publicly funded specialty treatment facilities during the HPSO era.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250248-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cross-sectional study pooled data from January 1, 2015, to December 31, 2021, from the Treatment Episode Data Set-Discharges, a national dataset managed by the Substance Abuse and Mental Health Services Administration that tracks annual discharges from state-licensed, publicly funded substance use treatment facilities. Individuals who were pregnant at the time of admission, reported an opioid (heroin, nonprescription methadone, or other opiates and synthetics) as their primary substance, and were discharged from ambulatory, nonintensive outpatient facilities were included. Data were analyzed November 2023 to April 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250248-7\"><jats:title>Exposure<\/jats:title><jats:p>MOUD inclusion in a treatment episode.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250248-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The main outcome was treatment retention (length of stay &amp;amp;gt;6 months vs \u22646 months). To account for the nonrandom assignment to MOUD, inverse probability of treatment\u2013weighted logistic regression models were estimated adjusting for sociodemographics; substance use, mental health, and treatment history; treatment admission\u2013related variables; census division; state policy characteristics; and year fixed effects.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250248-9\"><jats:title>Results<\/jats:title><jats:p>Of 29\u202f981 treatment episodes, most involved individuals aged 25 to 34 years (19\u202f106 [63.7%]). Approximately two-thirds of 29\u202f071 episodes in the final analysis (19\u202f884 [68.4%]) included MOUD across all study years. From 2015 to 2021, MOUD inclusion in treatment episodes increased by 9.1 percentage points, from 65.0% to 74.1%. Treatment episodes with MOUD were associated with greater odds of 6-month treatment retention compared with those without MOUD (adjusted odds ratio, 1.86 [95% CI, 1.72-2.01]). This finding translated to an estimated 14.2 percentage point greater adjusted probability of 6-month retention among treatment episodes with MOUD (43.1%) vs those without it (28.9%).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi250248-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cross-sectional study of treatment episodes from ambulatory, nonintensive facilities, MOUD inclusion among pregnant individuals was associated with significant improvements in treatment retention. However, retention remained low during the HPSO era. These findings underscore the importance of MOUD in improving OUD-related outcomes in this high-risk population.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.6069","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:31:02Z","timestamp":1745249462000},"page":"e256069","source":"Crossref","is-referenced-by-count":9,"title":["Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals"],"prefix":"10.1001","volume":"8","author":[{"given":"Valerie S.","family":"Ganetsky","sequence":"first","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Center for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alene","family":"Kennedy-Hendricks","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"3","key":"zoi250248r1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamapsychiatry.2023.4523","article-title":"Pregnancy and postpartum drug overdose deaths in the US before and during the COVID-19 pandemic.","volume":"81","author":"Han","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"21","key":"zoi250248r3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1001\/jama.2022.17045","article-title":"US Trends in drug overdose mortality among pregnant and postpartum persons, 2017-2020.","volume":"328","author":"Bruzelius","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"zoi250248r4","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Committee opinion No. 711: opioid use and opioid use disorder in pregnancy.","volume":"130","author":"American College of Obstetricians and Gynecologists Committee on Obstetric Practice and American Society of Addiction Medicine","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"12","key":"zoi250248r6","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1111\/add.15582","article-title":"Outcomes associated with the use of medications for opioid use disorder during pregnancy.","volume":"116","author":"Krans","year":"2021","journal-title":"Addiction"},{"issue":"12","key":"zoi250248r7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/add.13462","article-title":"Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.","volume":"111","author":"Zedler","year":"2016","journal-title":"Addiction"},{"issue":"3","key":"zoi250248r8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/ADM.0000000000000308","article-title":"Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance.","volume":"11","author":"Klaman","year":"2017","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250248r9","doi-asserted-by":"publisher","first-page":"424.e1","DOI":"10.1016\/j.ajog.2021.04.210","article-title":"Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.","volume":"225","author":"Schiff","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"zoi250248r10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/08897077.2022.2074604","article-title":"Opioid use disorder cascade of care framework design: a roadmap.","volume":"43","author":"Williams","year":"2022","journal-title":"Subst Abus"},{"issue":"5","key":"zoi250248r11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/AOG.0000000000003231","article-title":"Medication-assisted treatment use among pregnant women with opioid use disorder.","volume":"133","author":"Krans","year":"2019","journal-title":"Obstet Gynecol"},{"key":"zoi250248r12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jsat.2018.04.003","article-title":"Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States.","volume":"89","author":"Short","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"zoi250248r13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.drugalcdep.2015.02.012","article-title":"Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.","volume":"149","author":"Wilder","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi250248r14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1360-0443.2006.01651.x","article-title":"Methadone in pregnancy: treatment retention and neonatal outcomes.","volume":"102","author":"Burns","year":"2007","journal-title":"Addiction"},{"issue":"1","key":"zoi250248r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03630242.2019.1610829","article-title":"Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment.","volume":"60","author":"Jancaitis","year":"2020","journal-title":"Women Health"},{"key":"zoi250248r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104342","article-title":"Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.","volume":"126","author":"Curran","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi250248r17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/AOG.0000000000004307","article-title":"Predictors of initiation of medication for opioid use disorder and retention in treatment among U.S. pregnant women, 2013-2017.","volume":"137","author":"Nguemeni Tiako","year":"2021","journal-title":"Obstet Gynecol"},{"key":"zoi250248r18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jsat.2017.01.011","article-title":"Substance use, treatment, and demographic characteristics of pregnant women entering treatment for opioid use disorder differ by United States census region.","volume":"76","author":"Hand","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"zoi250248r20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jhealeco.2018.06.004","article-title":"The role of health insurance on treatment for opioid use disorders: evidence from the Affordable Care Act Medicaid expansion.","volume":"60","author":"Meinhofer","year":"2018","journal-title":"J Health Econ"},{"issue":"4","key":"zoi250248r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1588","article-title":"Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion.","volume":"1","author":"Saloner","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi250248r22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1377\/hlthaff.2021.01755","article-title":"Prenatal substance use policies and infant maltreatment reports.","volume":"41","author":"Maclean","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi250248r23","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/1468-0009.12591","article-title":"Development and implementation of state and federal child welfare laws related to drug use in pregnancy.","volume":"100","author":"McCOURT","year":"2022","journal-title":"Milbank Q"},{"issue":"1","key":"zoi250248r25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research.","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"issue":"4","key":"zoi250248r26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40471-017-0131-y","article-title":"Propensity scores in pharmacoepidemiology: beyond the horizon.","volume":"4","author":"Jackson","year":"2017","journal-title":"Curr Epidemiol Rep"},{"issue":"6","key":"zoi250248r27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2018.21554","article-title":"Using the E-value to assess the potential effect of unmeasured confounding in observational studies.","volume":"321","author":"Haneuse","year":"2019","journal-title":"JAMA"},{"key":"zoi250248r28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis.","volume":"71","author":"Ciccarone","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"10","key":"zoi250248r29","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1111\/add.15942","article-title":"Rapid changes in illegally manufactured fentanyl products and prices in the United States.","volume":"117","author":"Kilmer","year":"2022","journal-title":"Addiction"},{"issue":"5","key":"zoi250248r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.5734","article-title":"Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts.","volume":"3","author":"Schiff","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250248r31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/ADM.0000000000000827","article-title":"Medication for addiction treatment and postpartum health care utilization among pregnant persons with opioid use disorder.","volume":"16","author":"Ahrens","year":"2022","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250248r32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/AOG.0000000000005117","article-title":"Initiation and treatment discontinuation of medications for opioid use disorder in pregnant people compared with nonpregnant people.","volume":"141","author":"Xu","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi250248r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: a systematic review.","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"key":"zoi250248r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108028","article-title":"Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: differences in retention and completion among opioid-related discharges in 2016.","volume":"114","author":"Askari","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"zoi250248r35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","article-title":"Prescribing decisions at buprenorphine treatment initiation: do they matter for treatment discontinuation and adverse opioid-related events?","volume":"105","author":"Meinhofer","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"24","key":"zoi250248r36","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure.","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250248r37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/dom.14603","article-title":"Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review.","volume":"24","author":"Evans","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"zoi250248r38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13098-022-00785-1","article-title":"Adherence and persistence rates of major antidiabetic medications: a review.","volume":"14","author":"Lee","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"zoi250248r39","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s11606-020-06447-0","article-title":"The impact of social determinants of health on medication adherence: a systematic review and meta-analysis.","volume":"36","author":"Wilder","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi250248r40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward.","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"1","key":"zoi250248r41","doi-asserted-by":"publisher","first-page":"B5","DOI":"10.1016\/j.ajog.2019.03.022","article-title":"Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine.","volume":"221","author":"Ecker","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"zoi250248r42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","article-title":"Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts.","volume":"132","author":"Schiff","year":"2018","journal-title":"Obstet Gynecol"},{"key":"zoi250248r43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2017.12.001","article-title":"Predictors of treatment retention in postpartum women prescribed buprenorphine during pregnancy.","volume":"86","author":"O\u2019Connor","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi250248r44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities.","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi250248r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20843","article-title":"Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States.","volume":"3","author":"Huhn","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi250248r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108424","article-title":"Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: a state-level trends analysis.","volume":"132","author":"Solomon","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi250248r47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2019.12.005","article-title":"Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings.","volume":"110","author":"Meinhofer","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"zoi250248r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100239","article-title":"Prevalence and predictors of medication for opioid use disorder among reproductive-aged women.","volume":"11","author":"Bello","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"issue":"6","key":"zoi250248r49","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.whi.2016.09.002","article-title":"A moral or medical problem? the relationship between legal penalties and treatment practices for opioid use disorders in pregnant women.","volume":"26","author":"Angelotta","year":"2016","journal-title":"Womens Health Issues"},{"key":"zoi250248r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108765","article-title":"\u201cYou have to take this medication, but then you get punished for taking it:\u201d lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.","volume":"139","author":"Schiff","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi250248r51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.","volume":"95","author":"Samples","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"zoi250248r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? a national study of outpatient specialty treatment settings.","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"zoi250248r53","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1080\/10826084.2022.2083174","article-title":"Buprenorphine compared with methadone in pregnancy: a systematic review and meta-analysis.","volume":"57","author":"Kinsella","year":"2022","journal-title":"Subst Use Misuse"},{"issue":"9","key":"zoi250248r54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl.","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi250248r55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: a review.","volume":"17","author":"Grande","year":"2023","journal-title":"J Addict Med"},{"issue":"7","key":"zoi250248r56","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s10995-023-03614-7","article-title":"Opioid use disorder and overdose in the first year postpartum: a rapid scoping review and implications for future research.","volume":"27","author":"Frankeberger","year":"2023","journal-title":"Matern Child Health J"},{"key":"zoi250248r2","unstructured":"Pregnancy-related deaths: data from maternal mortality review committees in 36 U.S. states, 2017-2019. Division of Reproductive Health, Centers for Disease Control and Prevention. Accessed February 10, 2025. https:\/\/www.cdc.gov\/maternal-mortality\/php\/data-research\/mmrc-2017-2019.html"},{"key":"zoi250248r5","unstructured":"Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. Substance Abuse and Mental Health Services Administration. Accessed February 10, 2025. https:\/\/store.samhsa.gov\/sites\/default\/files\/sma18-5054.pdf"},{"key":"zoi250248r19","unstructured":"Quality ID #468 (NQF 3175): continuity of pharmacotherapy for opioid use disorder (OUD). National Quality Forum. 2019. Accessed February 10, 2025. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2019_Measure_468_MIPSCQM.pdf"},{"key":"zoi250248r24","unstructured":"State laws and policies: substance use during pregnancy. Guttmacher Institute. Accessed February 10, 2025. https:\/\/www.guttmacher.org\/state-policy\/explore\/substance-use-during-pregnancy?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833024\/ganetsky_2025_oi_250248_1744660352.2067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:31:06Z","timestamp":1745249466000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.6069","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}